Vector Innovation Fund Revenue and Competitors

Luxembourg,

Location

N/A

Total Funding

Investments

Industry

Estimated Revenue & Valuation

  • Vector Innovation Fund's estimated annual revenue is currently $681k per year.(i)
  • Vector Innovation Fund's estimated revenue per employee is $113,500

Employee Data

  • Vector Innovation Fund has 6 Employees.(i)
  • Vector Innovation Fund grew their employee count by 0% last year.

Vector Innovation Fund's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
N/A0N/AN/AN/A
#2
$329.2M101421%$8.7MN/A
#3
$25.4M11214%N/AN/A
#4
$6M33-34%N/AN/A
#5
$14.3M706%N/AN/A
#6
$8.2M450%N/AN/A
#7
$143.3M505-9%N/AN/A
#8
$582.2M1832-88%N/AN/A
#9
$74.9M3007%N/AN/A
#10
$30.2M13315%N/AN/A
Add Company

What Is Vector Innovation Fund?

The Vector Innovation Fund is a Reserved Alternative Investment Fund(RAIF) specialising in support for technology companies able to transform global markets, notably in global healthcare, innovation, sustainability and longevity. These transformational technologies may come from the nanotechnology, biotech, Al and machine learning, foodtech, cleantech and spacetech sectors. The Vector Innovation Fund (VIF) is a Reserved Alternative Investment Fund based in Luxembourg and offers all the benefits an international investor would require. The first subfund of VIF is a Pandemic Protection Fund. The VIF's role is to complement and strengthen capital support to any company with significant technology, IP, plus a world-class management team able to demonstrate delivery of commercial objectives in a market greatly in need of this solution.

keywords:N/A

N/A

Total Funding

6

Number of Employees

$681k

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vector Innovation Fund News

2022-04-19 - FlexShares Expands ESG & Climate Suite with Emerging ...

This fund builds on FlexShares' existing climate suite introduced in ... The full suite utilizes the Northern Trust ESG Vector Score** as...

2022-04-17 - Oxford Biomedica Preliminary Results

With the outsourced vector manufacturing supply market growing rapidly, ... capital injection into Oxford Biomedica Solutions to fund growth.

2022-04-06 - Myzorhynchus series of Anopheles mosquitoes as potential ...

This study aimed to identify the vector(s) of Plasmodium bubalis. ... Unit and Thailand Science Research and Innovation Fund Chulalongkorn...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.6M6N/AN/A
#2
$1.3M10-29%N/A
#3
$1.4M100%N/A
#4
$1.2M11-8%N/A
#5
$1.6M13-7%N/A